Fig. 2 a .

Results of two-way model sensitivity analysis comparing ranges of cost of integrated mutational profiling (X-axis) vs. diagnostic sensitivity of the PathFinder TG assay in differentiating mucinous from non-mucinous PCNs. For most possible costs and sensitivities, PFTG strategy is preferred (green), except where the cost of PFTG is too high (blue). b Results of two-way sensitivity analysis comparing ranges of sensitivity of PathFinder TG vs. sensitivity of CEA in differentiating mucinous from non-mucinous cysts. PFTG is preferred except in areas marked by blue (low sensitivity of PFTG and relatively high CEA sensitivity). For reference, a ‘star’ designates the baseline estimates in each nomogram.